<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Safeguards</title>
	<atom:link href="http://www.tapanray.in/tag/safeguards/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>No Compromise: India Protects Patents Act in High-Stakes UK Trade Pact</title>
		<link>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact</link>
		<comments>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/#comments</comments>
		<pubDate>Wed, 30 Jul 2025 06:47:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2025]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[data exclusivity]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[no compromise]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10948</guid>
		<description><![CDATA[India, the &#8220;pharmacy of the world,&#8221; has long been a lifeline for millions, churning out affordable generic medicines that make healthcare accessible across the Global South. With over $25 billion generic drug industry exporting half its production, India’s commitment to &#8230; <a href="http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Robust Patents, Not Tweaked Monopolies: India’s Practical Route to Affordable Medicines</title>
		<link>http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/#comments</comments>
		<pubDate>Fri, 30 May 2025 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advances]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[India’s Practical Route]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Tweaked]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10902</guid>
		<description><![CDATA[In April 2025, the United States Trade Representative (USTR) released its annual Special 301 Report, once again placing India on its &#8220;Priority Watch List&#8221; for intellectual property (IP) concerns. The report highlights persistent issues, particularly in the pharmaceutical sector, citing challenges &#8230; <a href="http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/robust-patents-not-tweaked-monopolies-indias-practical-route-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Balancing Strong IP Protection, Public Health Safeguards and Declining R&amp;D Productivity &#8211; A Crafty Gutsy Ball Game</title>
		<link>http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game</link>
		<comments>http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/#comments</comments>
		<pubDate>Mon, 16 Apr 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Balancing]]></category>
		<category><![CDATA[ball]]></category>
		<category><![CDATA[Crafty]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Strong]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=107</guid>
		<description><![CDATA[Pharmaceutical innovation has always been considered the lifeblood for the pharmaceutical industry and very rightly so. However, many studies do point out that such innovation has benefited the developed world more than the developing world. Product Price and Access: In &#8230; <a href="http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
